Gismo Therapeutics Inc.

Gismo Therapeutics Inc. is a biotech start-up company that has been pioneering advanced treatments for Alzheimer’s and Parkinson’s diseases since 2013. Founded in 2011, the company is focused on developing novel oral therapeutics for these debilitating conditions, based on a novel hypothesis and a novel mechanism of action. Gismo Therapeutics Inc. has garnered funding through a $235.00K grant investment at 03 December 2014, and has maintained ongoing research collaborations with US academic institutions. The company operates within the industries of Biotechnology, Health Care, Health and Wellness. Overall, Gismo Therapeutics Inc. exhibits a clear commitment to addressing unmet needs in neurodegenerative diseases through innovative means, as demonstrated by its focus on novel therapeutic approaches. The company has secured initial funding, and its collaboration with reputable US academic institutions signifies a strong foundation for research and development. However, the lack of headquarters information and details about the current investors may raise questions regarding the company's operational and financial transparency. Further insights into the company’s leadership, operational structure, and ongoing funding activities would provide a more comprehensive understanding of its potential for long-term success.